| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Lab | Pharmaceuticals& Drugs | 1,277.1 |
10 (0.79%) |
Mid Cap | 32,644 | 50.3 | 16.93 | 25.2 | 2.8 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,090.1 |
4.65 (0.43%) |
Mid Cap | 23,242 | 50.1 | 19.92 | 21.7 | 4 | |
| Lupin | Pharmaceuticals& Drugs | 2,272.3 |
23.6 (1.05%) |
Mid Cap | 22,708 | 116.6 | 14.55 | 19.3 | 4.6 | |
| Glenmark Pharma | Pharmaceuticals& Drugs | 2,175 |
-6.5 (-0.3%) |
Mid Cap | 13,322 | 48.3 | 9.67 | 45.2 | 5.9 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,477.3 |
13.65 (0.93%) |
Mid Cap | 10,933 | 42 | 15.17 | 34.9 | 3.7 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,343 |
-11.4 (-0.48%) |
Mid Cap | 9,498 | 49.4 | 18.61 | 47.7 | 5.9 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,268.5 |
-7.85 (-0.15%) |
Mid Cap | 8,813 | 182.8 | 23.18 | 28.9 | 4.5 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,625.5 |
5.55 (0.34%) |
Mid Cap | 6,635 | 44.6 | 12.45 | 36.3 | 5.2 | |
| Abbott India | Pharmaceuticals& Drugs | 25,940 |
105.85 (0.41%) |
Mid Cap | 6,409 | 730.4 | 22.1 | 35.4 | 11.5 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,437.6 |
10.4 (0.73%) |
Mid Cap | 5,554 | 16.5 | 5.63 | 86.8 | 14.5 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 2,963.9 |
16.25 (0.55%) |
Mid Cap | 4,648 | 84.5 | 19.35 | 34.9 | 8.1 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,169.3 |
2.75 (0.13%) |
Mid Cap | 3,749 | 61.2 | 23.42 | 35.4 | 16.2 | |
| Biocon | Pharmaceuticals& Drugs | 416.3 |
0.6 (0.14%) |
Mid Cap | 2,243 | 0.2 | 8.04 | 1,811.3 | 2.5 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 752.7 |
7.15 (0.96%) |
Mid Cap | 1,841 | 11.9 | 27.24 | 62.6 | 13.2 |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: